AG-126

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H5N3O3
Molecular Weight	215.165
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC(C=C(C#N)C#N)=CC=C1[N+]([O-])=O

InChI

InChIKey=DUQADSPERJRQBW-UHFFFAOYSA-N

InChI=1S/C10H5N3O3/c11-5-8(6-12)3-7-1-2-9(13(15)16)10(14)4-7/h1-4,14H

HIDE SMILES / InChI

Molecular Formula	C10H5N3O3
Molecular Weight	215.165
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20156166 | https://www.ncbi.nlm.nih.gov/pubmed/25731696 | https://www.ncbi.nlm.nih.gov/pubmed/17418876

AG-126 is the putative protein tyrosine kinase (PTK) inhibitor. It was found to rescue mice from lethal consequences of bacterial lipopolysaccharide (LPS) administration in a model of septic shock. AG126 treatment has beneficial effects in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. AG126 alleviates the clinical symptoms, diminishes encephalitogenic Th17 differentiation, reduces inflammatory CNS infiltration as well as microglia activation and attenuates myelin damage. AG-126 have recently been shown to protect from acute kidney injury in experimental animal models of ischemia-reperfusion and sepsis-induced injury. AG-126 modulates secondary damage in experimental spinal cord trauma.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
NRF2 pathway 7 Target ID: WP2884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27178899	Activator 1447
Tyrosine-protein kinase BTK 24 Target ID: CHEMBL5251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25731696	Inhibitor 8504
Apoptosis 156 Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17418876	Inhibitor 8504
Epidermal growth factor receptor 49 Target ID: CHEMBL2363049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3263702	Inhibitor 8504	150.0 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Diabetes mellitus 93 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27178899	Primary	Basic research	Unknown Approved Use Unknown
Multiple sclerosis 107 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25731696	Preventing	Preclinical	Unknown Approved Use Unknown
Spinal cord trauma 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17418876	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Aromatic malononitriles stimulate the resistance of insulin-producing beta-cells to oxidants and inflammatory cytokines.	2016-08-05	27178899
Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism.	2015-06	25731696
Inhibition of host extracellular signal-regulated kinase (ERK) activation decreases new world alphavirus multiplication in infected cells.	2014-11	25261871
Stage-specific expression of TNFα regulates bad/bid-mediated apoptosis and RIP1/ROS-mediated secondary necrosis in Birnavirus-infected fish cells.	2011-02-03	21304825
Regulation of lipopolysaccharide-induced inducible nitric-oxide synthase expression through the nuclear factor-kappaB pathway and interferon-beta/tyrosine kinase 2/Janus tyrosine kinase 2-signal transducer and activator of transcription-1 signaling cascades by 2-naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), a new synthetic isoquinoline alkaloid.	2007-02	17108235
A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling.	2006-04	16373689
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.	1989-10	2552117

Patents

Sample Use Guides

In Vivo Use Guide

Mice: 500 ug/animal for 3 consecutive days

Route of Administration: Intraperitoneal

In Vitro Use Guide

Pretreatment with AG-126 for 2 h and subsequent exposure of MIN6 cells to IL-1β and IFNγ at the presence of 25 uM AG-126 restored the glucose stimulatory index.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:52:23 GMT 2025` Edited by `admin` on `Mon Mar 31 19:52:23 GMT 2025`
Record UNII	7YA4AMD1JC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AG-126

Common Name

English

TYRPHOSTIN A-10

Preferred Name

English

TYRPHOSTIN AG-126

Common Name

English

PROPANEDINITRILE, 2-((3-HYDROXY-4-NITROPHENYL)METHYLENE)-

Systematic Name

English

Code System Code Type Description

FDA UNII

7YA4AMD1JC

Created by admin on Mon Mar 31 19:52:23 GMT 2025 , Edited by admin on Mon Mar 31 19:52:23 GMT 2025

PRIMARY

EPA CompTox

DTXSID80152117

Created by admin on Mon Mar 31 19:52:23 GMT 2025 , Edited by admin on Mon Mar 31 19:52:23 GMT 2025

PRIMARY

PUBCHEM

2046

Created by admin on Mon Mar 31 19:52:23 GMT 2025 , Edited by admin on Mon Mar 31 19:52:23 GMT 2025

PRIMARY

CAS

118409-62-4

Created by admin on Mon Mar 31 19:52:23 GMT 2025 , Edited by admin on Mon Mar 31 19:52:23 GMT 2025

PRIMARY

Related Record Type Details


					7YA4AMD1JC

AG-126

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20156166 | https://www.ncbi.nlm.nih.gov/pubmed/25731696 | https://www.ncbi.nlm.nih.gov/pubmed/17418876

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20156166 | https://www.ncbi.nlm.nih.gov/pubmed/25731696 | https://www.ncbi.nlm.nih.gov/pubmed/17418876